BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
Executive Summary
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.